Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA)

Anti-Cancer Drugs

Volumn 14, Issue 5, 2003, Pages 369-375

  Whitehouse, Pauline A ^a   Knight, Louise A ^a   Di Nicolantonio, Federica ^a   Mercer, Stuart J ^a   Sharma, Sanjay ^a   Cree, Ian A ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

Chemosensitivity; Colorectal cancer; Luciferase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASSAY; ATP TUMOR CHEMOSENSITIVITY ASSAY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER TISSUE; CELL HETEROGENEITY; CHEMOSENSITIVITY; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; EFFUSION; EXPERIMENTAL TEST; HUMAN; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; PREDICTION; PRIORITY JOURNAL; SOLID TUMOR; TISSUE SECTION;

ADENOCARCINOMA; ADENOSINE TRIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL INFECTIONS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY CONTROL; TUMOR CELLS, CULTURED;

EID: 0038517683     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200306000-00008     Document Type: Article

References (37)

1. Office for National Statistics. Mortality Statistics: Cause: Review of the Registrar General on Deaths by Cause, Sex and Age, in England and Wales, 1998. DH2; no. 25. London: Stationary Office; 2000.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
3. Advanced Colorectal Cancer Meta-Analysis Project. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-308.
4. NICE. Guidance on the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Technology Appraisal Guidance 33. London: National Institute for Clinical Excellence; 2002.
5. Maiello E, Gebbia V, Giuliani F, Paoletti G, Gebbia N, Cigolari S, et al. 5-flurouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicentre randomized phase II study of the Southern Italy Oncology Group. Ann Oncol 2000; 11:1045-1051.
6. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
7. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer. A multicentre randomised trial. Lancet 2000; 355:1041-1047.
8. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
10. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumours responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327.
11. Brown E, Markman M. Tumor chemosensitivity and chemoresistance assays. Cancer 1996; 77:1020-1025.
12. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55:5276-5282.
13. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EMM, Subedi AMC, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996; 7:630-635.
14. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, et al. Correlation of drug response with the ATP tumour chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000; 77:258-263.
15. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998; 9:51-57.
16. Hunter EM, Sutherland LA, Cree IA, Subedi AMC, Hartmann D, Andreotti PE. The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay. Anticancer Drugs 1994; 5:171-176.
17. Hunter EM, Sutherland LA, Cree IA, Dewar JA, Preece PE, Andreotti PE, Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 1993; 19:242-249.
18. Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, et al. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs 1999; 10:437-444.
19. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJE, Hungerford JL, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79;1487-1493.
20. Araki Y, Isomoto H, Matsumoto A, Kaibara A, Yasunaga M, Hayashi K, et al. An in vitro chemosensitivity test for colorectal cancer using collagen-gel droplet embedded cultures. Kurume Med J 1999; 46:163-166.
21. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995; 1:305-311.
22. Cree IA, Pazzagli M, Mini E, Mazzei T, Hunter EM, Sutherland LA, et al. Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonigenic assay. Anticancer Drugs 1995; 6:398-404.
23. Petty RD, Sutherland LA, Hunter EM, Cree IA. Comparison of the MTT and ATP-Based assays for the measurement of viable cell number. J Biolumin Chemilumin 1995; 10:29-34.
24. Zhengdong L, Duhong B. Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer. Chin Med J 1996; 109:353-355.
25. Poulain L, Sichel F, Crouet H, Bureau F, Gauduchon P, Gignoux M, et al. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells. Cancer Chemother Pharmacol 1997; 40:385-390.
26. Ferguson PJ, Currie C, Vincent MD. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal Amphotericin B and phospholipase A2-II. Drug Metab Dispos 1999; 27:1399-1405.
27. Morikage T, Ohmori T, Nishio K, Fujuwara Y, Takeda Y, Saijo N. Modulation of cisplatin sensitivity and accumulation by Amohotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res 1993; 53:3302-3307.
28. Ganu UK, Khandalekar DD, Gokhale SV. Inability of amphotericin B (Fungizone) or of sodium deoxycholate to alter natural drug resistance or sensitivity of transplanted murine leukaemias. Ind J Physiol Pharmac 1984; 28:21-26.
29. Iida N, Takara K, Ohmoto N, Nakamura T, Kimura T, Wada A, et al. Reversal effects of antifungal drugs on multidrug resistance in MDR1-overexpressing HeLa cells. Biol Pharm Bull 2001; 24:1032-1036.
30. Smith E, Lumley CE, Stratford IJ, Adams GE. Chemosensitization in vitro: potentiation of melphalan toxicity by misonidazole, metronidazole and nitrofurazone. Int J Radiat Oncol Biol Phys 1982; 8:615-617.
31. Jonsson E, Dhar S, Jonsson B, Nygren P, Graf W, Larsson R. Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cell but not in cell lines. Eur J Cancer 2000; 36:2120-2127.
32. Andreotti PE, Cree IA, Pazzagli M, Bruckner HW. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies. J Biolumin Chemilumin 1994; 9:373-378.
33. Cree IA, Andreotti PE. Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines. Toxicology In Vitro 1997; 11:553-556.
34. Aung TT, Davis MA, Ensiminger WD, Lawrence TS. Interaction between gemcitabine and mitomycin-C in vitro. Cancer Chemother Pharmacol 2000; 45:38-42.
35. Van Moorsel CJA, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, et al. Combination chemotherapy studies with gemcitabine. Semin Oncol 1997; 24(suppl 7):S7-17-S7-23.
36. Cree IA, Kurbacher CM. ATP-based tumor chemosensitivity testing: assisting new agent development. Anticancer Drugs 1999; 10:431-435.
37. Di Nicolantonio F, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, et al. Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer. Anticancer Drugs 2002; 13:625-630.